Caribou Biosciences

@CaribouBio

Leading clinical-stage CRISPR company developing a pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies for cancer.

Geregistreerd in juli 2014

Tweets

Je hebt @CaribouBio geblokkeerd

Weet je zeker dat je deze Tweets wilt bekijken? @CaribouBio wordt niet gedeblokkeerd door Tweets te bekijken.

  1. 4 uur geleden

    Thrilled to announce that the first patient has been dosed in our phase 1 clinical trial to evaluate a differentiated -edited allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma. Learn more:

    Ongedaan maken
  2. 22 jun.

    Delighted to welcome Scott Braunstein, M.D. as the newest member of our board of directors. Bringing over 20 years of industry experience, Dr. Braunstein will be invaluable as we advance our chRDNA-edited allogeneic cell therapies. Learn more:

    Ongedaan maken
  3. 9 jun.

    🎉 Congratulations to our President and CEO, Rachel Haurwitz, on being named to the inaugural class of ’s New Economy Catalysts amongst innovators focused on accelerating solutions. Learn about the & upcoming live event:

    Ongedaan maken
  4. 3 jun.

    Our CEO, Rachel Haurwitz, participated in last week’s entrepreneurship panel to discuss challenges & opportunities in starting a biotech company. She was joined by other leaders in the field from , , , MiRXES & CircCode.

    Ongedaan maken
  5. 17 mei

    Thrilled to welcome Drs. Katy Rezvani & Christopher Sturgeon as members of our Scientific Advisory Board. Drs. Rezvani & Sturgeon will bring invaluable experience and insights as we develop genome-edited iPSC-derived NK cell therapies: Learn more:

    Ongedaan maken
  6. 10 mei

    We’re excited to share Caribou’s new website! Check it out here:

    Ongedaan maken
  7. 5 mei

    Delighted to welcome Andrew Guggenhime as the newest member of our board of directors. With 20+ years of industry experience, his insights & expertise will help guide Caribou's evolution and strategy. Learn more:

    Ongedaan maken
  8. 16 apr.

    Pleased to share that our CEO, Rachel Haurwitz, is once again featured on the annual “Power List,” which honors inspirational professionals involved in drug discovery and development of advanced medicines.

    Ongedaan maken
  9. 15 apr.

    We’re excited to share that our CEO, Rachel Haurwitz, is featured in the latest edition of the podcast. She talks about her academic background, designing a new generation of and the founding of Caribou! Listen to the podcast here:

    Ongedaan maken
  10. 31 mrt.

    Thank you for the wonderful piece on our CEO Rachel Haurwitz, her journey in founding Caribou and the promise of our technology.

    Ongedaan maken
  11. 3 mrt.

    We’re delighted to announce the completion of a $115M Series C financing to advance our next-generation technologies and allogenic cell therapies for .

    Ongedaan maken
  12. 10 feb.

    We are thrilled to announce a collaboration & multi-year license agreement for CAR-T cell products with allowing for the potential to develop next-generation “off-the-shelf” cellular therapies to benefit a broader patient population. Read More:

    Ongedaan maken
  13. 9 feb.

    Delighted to welcome Jason O’Byrne as our Chief Financial Officer. Jason's deep experience in high-growth biotech environments and expertise in the genetic medicines space make him an ideal addition to our executive leadership team. Read more:

    Ongedaan maken
  14. 18 nov. 2020

    Excited to announce an exclusive license agreement with giving Caribou rights to fully human anti-CD371 scFvs for allogeneic . This gives Caribou the opportunity to develop new therapies w/ significant impact for AML or MDS.

    Ongedaan maken
  15. 7 okt. 2020

    Unbelievably proud of our co-founder, Jennifer Doudna, and colleague, , for winning the in for their cutting-edge development of the CRISPR-Cas9 method. Read more about the exciting news here:

    Ongedaan maken
  16. 8 sep. 2020

    Thrilled to announce that the has cleared Caribou’s first IND for a CRISPR -edited off-the-shelf allogeneic anti-CD19 CAR-T candidate for patients with relapsed/refractory B cell non-Hodgkin . Read more here:

    Ongedaan maken
  17. 9 jun. 2020

    Learn about innovation & strategic thinking happening outside of the lab from our chief legal officer, Barbara McClung, who discussed all things , & negotiations on ’s panels. Register & stream Barbara’s panels:

    Ongedaan maken
  18. 8 jun. 2020

    Excited for this year’s conference! Register for and stream the True North panel to hear insights and lessons learned in pursuing big ideas from our president & CEO, Rachel Haurwitz.

    Ongedaan maken
  19. 11 mei 2020

    Thrilled to welcome Cherry Thomas, MD, as our SVP of Clinical Development. Dr. Thomas offers a wealth of expertise in & which will be integral in leading the initiation of our first clinical trial this year.

    Ongedaan maken
  20. 28 feb. 2020

    Would you like to be part of our exciting team? Caribou is growing and we need diverse, dedicated, and driven folks who can help us achieve our mission. Check out our job openings and we can’t wait to hear from you.

    Ongedaan maken

Het laden lijkt wat langer te duren.

Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.

    Je bent misschien ook geïnteresseerd in

    ·